Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?

Eli Lilly (NYSE: LLY | LLY Price Prediction) and JPMorgan Chase (NYSE: JPM) both have market caps around $800 billion, putting them in a live race to a $1 trillion market cap. With Lilly at roughly $829 billion and JPMorgan at roughly $798 billion, the gap between them and the milestone is measured in months, not decades. The question is which gets there first, and the data points clearly in one direction.

Growth Trajectory

This is the most decisive dimension in the comparison. Lilly’s GLP-1 franchise is generating revenue growth that almost no large-cap company has ever sustained at this scale. Full-year 2025 revenue totaled $65.18 billion, up 44.7% year-over-year, with net income rising 94.9% to $20.64 billion. Mounjaro alone posted $7.41 billion in Q4 2025, up 110% year-over-year, while Zepbound delivered $4.26 billion, up 123%. Forward EPS growth is projected at 51.4% year-over-year, with 2026 revenue guidance set at $80 billion to $83 billion.

JPMorgan’s growth story is solid but structurally different. Full-year 2025 net income was $57.05 billion, down 2.43% year-over-year, with forward EPS growth at −3.6%. The bank’s headline revenue figures are distorted by a prior-year Visa gain, but even stripping that out, organic growth is single-digit. The federal funds rate has slipped to 3.63%, offering some net interest margin support, with limited capacity to drive explosive earnings expansion.

Winner: Eli Lilly.

Analyst Conviction

The analyst community has spoken with unusual clarity: 80% of analysts covering Lilly are bullish, with a consensus price target of $1,209.21. That target implies a stock price already above the $1 trillion market cap threshold. JPMorgan has 52% analyst bullishness with a consensus target of $337.75.

In October 2025, Jim Cramer named JPMorgan “the most likely company to hit $1 trillion next” when sizing up a field that included Lilly, Oracle, Walmart, Visa, and Mastercard. The data since then has moved decisively against that call. Lilly’s market cap has pulled ahead, its earnings beats have been consistent, and, as mentioned, the analyst target now sits well above the $1 trillion implied price.

Winner: Eli Lilly.

Path to $1 Trillion

Lilly needs less incremental appreciation to cross the threshold. At a current market cap near $829 billion, it requires approximately $171 billion in additional value. JPMorgan, at roughly $798 billion, needs closer to $202 billion. Lilly already traded above $1,000 per share in early 2026, demonstrating the market has briefly priced it at that level. The pipeline adds further runway: orforglipron, an oral GLP-1, has been submitted for approval in the U.S., Japan, and the EU, and retatrutide Phase 3 trials showed weight loss up to 71.2 lbs. JPMorgan’s path requires sustained macro cooperation: stable rates, contained credit losses, and continued capital markets activity, all of which are outside the company’s control.

Winner: Eli Lilly.

Verdict

For a retirement-focused investor who wants steady income and capital preservation with modest upside, JPMorgan remains a defensible core holding. Its 2.0% dividend yield, $50 billion buyback program, and forward P/E of 14x make it a low-drama compounder.

Yet, the investor who wants to own the stock that hits $1 trillion first owns Lilly. The GLP-1 supercycle is still expanding internationally, the oral incretin pipeline opens an entirely new addressable market, and the analyst consensus target of $1,209.21 already prices in the milestone. Lilly gets there first, and it is not particularly close.